You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Raw chart and full-history price indicators begin at the captured split on Nov 14, 2023; bars on opposite sides are not compared.
XORTX Therapeutics Inc. plans a Health Canada application for XRx-026, supporting a two-part XRX-OXY-102 study evaluating XORLO™ for gout; conducting the first part in Canada is expected to accelerate clinical data for a planned FDA New Drug Application.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XRTX
this stock
XORTX Therapeutics Inc.
|
$1.67M | — | — | — | 6.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$137.57B | +19.7% | +46.2% | 34.9 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.40B | +23.2% | +20.8% | 21.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$93.61B | +684.5% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
XORTX Therapeutics Inc. plans a Health Canada application for XRx-026, supporting a two-part XRX-OXY-102 study evaluating XORLO™ for gout; conducting the first part in Canada is expected to accelerate clinical data for a planned FDA New Drug Application.
ViewRaw-price comparisons begin at the captured split on Nov 14, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XRTX | +0.0% | -35.2% | -57.8% | -8.0% | -67.3% |
| SPY | +3.3% | -1.9% | +1.5% | +0.2% | +11.0% |
| vs SPY | -3.3% | -33.3% | -59.3% | -8.2% | -78.3% |
